ASCO 2020 | Hypomethylating agents in AML

Name: Hypomethylating agents in AML
Uploaded: 2020-06-01T00:00:00Z
Duration: 3 min 8 s
Description: Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, outlines the advantages and underuse of hypomethylating agents in acute myeloid leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Amer Zeidan • 1 Jun 2020

ASCO 2020

Acute Myeloid Leukemia Leukemia Azacitidine Decitabine

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, outlines the advantages and underuse of hypomethylating agents in acute myeloid leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).